High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations
暂无分享,去创建一个
P. Maison-Blanche | G. Jondeau | A. Leenhardt | C. Boileau | I. Denjoy | M. Abifadel | F. Extramiana | G. Delorme | V. Fressart | C. Bouleti | F. Arnoult | A. Uccellini | O. Milleron | S. Elbitar | M. Langeois | M. Spentchian | F. Iserin
[1] Klaus Romero,et al. CredibleMeds.org: What does it offer? , 2018, Trends in cardiovascular medicine.
[2] S. Lemaire,et al. International Registry of Patients Carrying TGFBR1 or TGFBR2 MutationsCLINICAL PERSPECTIVE , 2016 .
[3] Andrea Mazzanti,et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.
[4] F. Tubach,et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. , 2015, European heart journal.
[5] Sabino Iliceto,et al. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death , 2015, Circulation.
[6] S. Priori,et al. Genetic modulators of the phenotype in the long QT syndrome: state of the art and clinical impact. , 2015, Current opinion in genetics & development.
[7] V. Aboyans,et al. [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2015, Kardiologia polska.
[8] J. Cross,et al. Role of Mutation and Pharmacologic Block of Human KCNH2 in Vasculogenesis and Fetal Mortality: Partial Rescue by Transforming Growth Factor-&bgr; , 2015, Circulation. Arrhythmia and electrophysiology.
[9] Beatriz Trenor,et al. Electrophysiological and Structural Remodeling in Heart Failure Modulate Arrhythmogenesis. 1D Simulation Study , 2014, PloS one.
[10] P. Robinson,et al. Observational Cohort Study of Ventricular Arrhythmia in Adults with Marfan Syndrome Caused by FBN1 Mutations , 2013, PloS one.
[11] C. Tracy,et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.
[12] S. Willems,et al. Prospective risk stratification of sudden cardiac death in Marfan's syndrome. , 2013, International journal of cardiology.
[13] M. Halushka,et al. TGFβ Receptor Mutations Impose a Strong Predisposition for Human Allergic Disease , 2013, Science Translational Medicine.
[14] M. Enriquez-Sarano,et al. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. , 2013, Journal of the American College of Cardiology.
[15] Yanjie Lu,et al. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome. , 2012, Cardiovascular research.
[16] D. Milewicz,et al. TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. , 2010, Cardiovascular research.
[17] Laurence Faivre,et al. The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.
[18] P. Ravaud,et al. Comparison of Clinical Presentations and Outcomes Between Patients With TGFBR2 and FBN1 Mutations in Marfan Syndrome and Related Disorders , 2009, Circulation.
[19] P. Kwok,et al. Association of TGFBR2 polymorphism with risk of sudden cardiac arrest in patients with coronary artery disease. , 2009, Heart rhythm.
[20] E. W. Hancock,et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the , 2009, Journal of the American College of Cardiology.
[21] S. Priori,et al. High Efficacy of β-Blockers in Long-QT Syndrome Type 1: Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of β-Blocker Treatment “Failures” , 2009, Circulation.
[22] Wolfram Kress,et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.
[23] Yusuke Nakamura,et al. Heterozygous TGFBR2 mutations in Marfan syndrome , 2004, Nature Genetics.
[24] B. McCrindle,et al. General cardiology: abstractLong-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death?☆ , 2003 .
[25] L. Jordaens,et al. Cardiac Effects of Chronic Oral Beta‐Blockade: , 2002, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[26] G. Breithardt,et al. Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .
[27] I. Kaitila,et al. Abnormal ambulatory electrocardiographic findings in patients with the Marfan syndrome , 1997, Journal of internal medicine.
[28] R E Pyeritz,et al. Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.
[29] J. Weissenbach,et al. A second locus for Marfan syndrome maps to chromosome 3p24.2–p25 , 1994, Nature Genetics.
[30] T. Graham. Comparison of Clinical Presentations and Outcomes Between Patients With TGFBR2 and FBN1 Mutations in Marfan Syndrome and Related Disorders , 2011 .
[31] S. Priori,et al. High Efficacy of (cid:1) -Blockers in Long-QT Syndrome Type 1 Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of (cid:1) -Blocker Treatment “Failures” , 2009 .
[32] Thomas R. Riley,et al. A Randomized Double-blind Placebo-controlled Trial , 2004 .
[33] P W Macfarlane,et al. Effects of age, sex, and race on ECG interval measurements. , 1994, Journal of electrocardiology.
[34] E. T. Murphy. What Does It Offer , 1962 .